D trial of very active antiretroviral therapy versus highly active antiretroviral

D trial of extremely active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive sufferers with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012; 60:150157. [PubMed: 22395672] 49. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol. 1996; 14:2353364. [PubMed: 8708728] 50. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998; 16:68391. [PubMed: 9469358]Author Manuscript Author Manuscript Author Manuscript Author ManuscriptCurr Opin HIV AIDS. Author manuscript; obtainable in PMC 2018 December 31.Goncalves et al.Page51. Cooley T, Henry D, Tonda M, et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Oncologist. 2007; 12:11423. [PubMed: 17227906] 52. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for sophisticated human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010; 116:3969977. [PubMed: 20564162] 53. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine within the treatment of AIDS-related Kaposi’s sarcoma: final results of a randomized phase III clinical trial. J Clin Oncol. 1998; 16:2445451. [PubMed: 9667262] 54. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma.Naringin Inducer J Clin Oncol.Tetraethylammonium perchlorate 1998; 16:11121121. [PubMed: 9508198] 55. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in individuals with advanced AIDS-related Kaposi sarcoma. Cancer. 2002; 95:14754. [PubMed: 12115328] 56. Polizzotto MN, Uldrick T, Wyvill K, et al. Pomalidomide for Kaposi Sarcoma in individuals with and without HIV: A phase I/II study. J. Clinical Oncology. 2016 * Pomalidomide was well tolerated in sufferers with KS (both with and with out HIV infection) at 5mg orally day-to-day for 21 out of 28 days. The overall response price was 68 , with 18 comprehensive responses. 57. Polizzotto MN, Sereti I, Uldrick T, et al. Pomalidomide induces expansion of activated and central memory CD4+ and CD8+ T cells in vivo in patients with and without having HIV infection.PMID:23381601 Blood. 2014; 124:4128128. * Sufferers with Kaposi sarcoma treated with pomalidomide showed significant increases inside the quantity of CD4 and CD8 T cells. 58. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an efficient and protected drug for AIDS-related Kaposi’s sarcoma: benefits of a phase II study. J Clin Oncol. 2000; 18:1550557. [PubMed: 10735904] 59. Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002; 20:3236241. [PubMed: 12149296] 60. Iuliano F, Cervo G, Iuliano E, et al. Weekly nab-paclitaxel in elderly patients with classic Kaposi sarcoma. 2016 American Society of Clinical Oncology Annual Meeting. 2016Abstract e22539 * Short article describing the usage of weekly nab-.